


# Stabilis



## Chlorpromazine hydrochloride



Noms commerciaux

Ampliactil	Argentine
Amplictil	Brésil
Cain	Inde
Chlorazin	Suisse
Chlorpromazine	Canada, Etats Unis d'Amérique, Grande Bretagne, Irlande, Malaisie
Clomactel	Pérou
Clorpromazina	Argentine, Chili, Equateur, Italie, Pérou, Vénézuéla
Fenactil	Pologne
Hibernal	Hongrie, Suède
Largactil	Australie, Espagne, France, Grande Bretagne, Irlande, Italie, Maroc, Mexique, Nouvelle Zélande, Pays bas, Portugal, Tunisie, Turquie, Vénézuéla
Normazine	Iran
Propaphenin	Allemagne
Zuledin	Grèce



### Stabilité des solutions

PE	POF	Concentration	Température	Stabilité	Durée	Compatibilité	Alertes	Documentation
PE	POF	0,25 mg/ml	20-25°C		8			1960
PE	POF	0,25 mg/ml	25°C		8			1522



### Stabilité en mélange

PE	PVC	Concentration	Température	Stabilité	Composition	Stabilité	Documentation
PE	PVC	6,25 mg/ml	25°C		Hydroxyzine dihydrochloride : 12,5 mg/ml Pethidine hydrochloride : 25 mg/ml	366	342
PE	PVC	6,25 mg/ml	4°C		Hydroxyzine dihydrochloride : 12,5 mg/ml Pethidine hydrochloride : 25 mg/ml	366	342



## Facteur influençant la stabilité

				1960
				1960










## Compatibilités

			307
			3
			921
			253
			99
			188
			3539
			1713
			3964
			1438
			299
			2087
			251
			3674
		<b>RL</b>	4603
			3012
			188
			1754
			1415
			1410
			301

		Chlorpromazine hydrochloride : 2 mg/ml Cladribine : 0.5 mg/ml		1496
		Chlorpromazine hydrochloride : 2 mg/ml Cladribine : 0.015 mg/ml		1496
		Chlorpromazine hydrochloride : 2 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Chlorpromazine hydrochloride : 2 mg/ml Famotidine : 2 mg/ml		215
		Chlorpromazine hydrochloride : 2 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Chlorpromazine hydrochloride : 2 mg/ml Filgrastim : 30 µg/ml		244
		Chlorpromazine hydrochloride : 5 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Chlorpromazine hydrochloride : 25 mg/ml Fluconazole : 2 mg/ml		496
		Chlorpromazine hydrochloride : 2 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Chlorpromazine hydrochloride : 5 mg/ml Furosemide : 1 mg/ml		1232
		Chlorpromazine hydrochloride : 0,26 mg/ml Furosemide : 5,21 mg/ml		1289
		Chlorpromazine hydrochloride : 2 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Chlorpromazine hydrochloride : 2 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Chlorpromazine hydrochloride : 10 mg/ml Heparin sodium : 1 UI/ml		1228
		Chlorpromazine hydrochloride Heparin sodium		3540
		Chlorpromazine hydrochloride : 10 mg/ml Heparin sodium : 1 UI/ml	RL	1228
		Chlorpromazine hydrochloride : 0,26 mg/ml Heparin sodium : 58,34 UI/ml		1289
		Chlorpromazine hydrochloride : 2 mg/ml Hetastarch : 60 mg/ml		1721
		Chlorpromazine hydrochloride Hyaluronidase		3184
		Chlorpromazine hydrochloride : 25 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
		Chlorpromazine hydrochloride : 25 mg/ml Hydrocortisone sodium succinate : 1 mg/ml	RL	1228
		Chlorpromazine hydrochloride : 25 mg/ml Hydroxyzine dihydrochloride : 50 mg/ml		188
		Chlorpromazine hydrochloride : 25 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Chlorpromazine hydrochloride : 2 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Chlorpromazine hydrochloride Linezolid		3560
		Chlorpromazine hydrochloride : 2 mg/ml Linezolid : 2 mg/ml		1925

		Chlorpromazine hydrochloride : 20 & 22.22 mg/ml Lorazepam : 0.44 & 0.8 mg/ml	∅	1724
		Chlorpromazine hydrochloride : 2 mg/ml Melphalan : 0.1 mg/ml	▲	169
		Chlorpromazine hydrochloride Methotrexate sodium		3637
		Chlorpromazine hydrochloride : 16.67 mg/ml Midazolam hydrochloride : 1.67 mg/ml	∅	404
		Chlorpromazine hydrochloride Morphine tartrate		519
		Chlorpromazine hydrochloride : 25 mg/ml N-acetylcysteine : 200 mg/ml	∅	3766
		Chlorpromazine hydrochloride : 25 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Chlorpromazine hydrochloride : 0.1 mg/ml Netilmicin sulfate : 3 mg/ml	▲◆	1200
		Chlorpromazine hydrochloride : 2 mg/ml Ondansetron hydrochloride : 1 mg/ml	▲	334
		Chlorpromazine hydrochloride : 2 mg/ml Oxaliplatin : 0,5 mg/ml	◆	1662
		Chlorpromazine hydrochloride : 2 mg/ml Paclitaxel : 1.2 mg/ml	◆	248
		Chlorpromazine hydrochloride Pantoprazole sodium		2090
		Chlorpromazine hydrochloride Penicillin G potassium		3596
		Chlorpromazine hydrochloride Pentobarbital sodium		3596
		Chlorpromazine hydrochloride Phenobarbital sodium		3596
		Chlorpromazine hydrochloride : 2 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml	◆	81
		Chlorpromazine hydrochloride : 25 mg/ml Potassium chloride : 40 mEq/l	RL	1228
		Chlorpromazine hydrochloride : 25 mg/ml Potassium chloride : 40 mEq/l	▲◆	1228
		Chlorpromazine hydrochloride : 0,26 mg/ml Potassium chloride : 1250 mEq/l	◆	1289
		Chlorpromazine hydrochloride : 2 mg/ml Propofol : 10 mg/ml	∅	300
		Chlorpromazine hydrochloride : 25 mg/ml Ranitidine hydrochloride : 25 mg/ml	∅	58
		Chlorpromazine hydrochloride : 2 mg/ml Remifentanil hydrochloride : 250 µg/ml	▲	59
		Chlorpromazine hydrochloride : 2 mg/ml Remifentanil hydrochloride : 25 µg/ml	▲	59
		Chlorpromazine hydrochloride : 25 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Chlorpromazine hydrochloride : 2 mg/ml Sargramostim : 10 µg/ml	▲	335
		Chlorpromazine hydrochloride : 2 mg/ml Teniposide : 0.1 mg/ml	◆	905

		Chlorpromazine hydrochloride : 25 mg/ml Thiopental sodium : 25 mg/ml		3767
		Chlorpromazine hydrochloride : 2 mg/ml Thiotepa : 1 mg/ml		249
		Chlorpromazine hydrochloride : 2 mg/ml Vinorelbine tartrate : 1 mg/ml		84



## Voie d'administration



## Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
58	Revue	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
188	Revue	Gibler B, Kim MS, Raleigh F. Visual compatibility of neuroleptics with anticholinergics or antihistamines in polyethylene syringes. Am J Hosp Pharm 1994 ; 51: 2709-2710.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.

244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
342	Revue	Conklin CA, Kerege JF, Christensen JM. Stability of an analgesic-sedative combination in glass and plastic single-dose syringes. Am J Hosp Pharm 1985 ; 42: 339-342.
404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
519	Revue	Poggi GL. Compatibility of morphine tartrate admixtures in polypropylene syringes. Aust J Hosp Pharm 1991 ; 21: 316.



905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1200	Revue	Chaudry IA, Bruey KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742.
1228	Revue	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1289	Revue	Hecq JD, Evrard JM, Gillet P, Grosdent N. Etude de stabilité visuelle du chlorhydrate de chlorpromazine, du chlorure de potassium, de la furosémide et de l'héparine sodique en perfusion continue. Pharmakon 1998 ; 116: 145-148.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1438	Revue	Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1522	Laboratoire	Macoflex N® Maco Pharma 2001
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.

1724	Revue	Elbe D, Condé C. Visual compatibility of various injectable neuroleptic agents with benzotropine and lorazepam in polypropylene syringes. Can J Hosp Pharm 2001 ; 54: 102-105.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1960	Revue	Kambia NK, Dine T, Dupin-Spriet T, Gressier B, Luycks M, Goudaliez F, Brunet C. Compatibility of nitroglycerin, diazepam and chlorpromazine with a new multilayer material for infusion containers. J Pharm Biomed Anal 2005 ; 37: 259-264.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3184	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product characteristics.
3216	Revue	CPHarmaceuticaLavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3539	Laboratoire	Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013
3540	Laboratoire	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3560	Laboratoire	Linezolid (Zyvox®) - Summary of Product Characteristics Pharmacia 2013
3596	Laboratoire	Chlorpromazine (Largactil®) - Summary of Product Characteristics Sanofi 2014
3637	Laboratoire	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.




3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.

# Stabilis



## Chlorpromazine hydrochloride



### Stabilité des préparations

		3500 mg	Orasweet ® >> 35 mL	2-8°C		90		3785
		3500 mg	Orasweet ® >> 35 mL	20-25°C		90		3785



### Compatibilités

	Chlorpromazine hydrochloride Lithium citrate	2630
	Chlorpromazine hydrochloride Lithium citrate	2466
	Chlorpromazine hydrochloride Thioridazine	2630





















### Bibliographie

Type	Source
2466 Revue	Theesen KA, Wilson JE, Newton DW, Ueda CT. Compatibility of lithium citrate syrup with 10 neuroleptic solutions Am J Hosp Pharm 1981 ; 38: 1750-1753.

2630	Revue	Raleigh F. Incompatibilities with orally administered liquid neuroleptic medication combinations. Hosp Pharm 1981 ; 16: 486-487.
3785	Revue	Prohotsky D.L, . Juba K.M, Zhao F. Formulation and Stability of an Extemporaneously Compounded Oral Solution of Chlorpromazine HCl J Pain Palliat Care Pharm 2014 ;,28, 4: 367?370.



# Dictionnaire

 Anxiolytique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polyéthylène
 NaCl 0,9% ou glucose 5%	 A l'abri de la lumière
 Heure	 Polyolefine
 Stabilité en mélange	 Solvant
 Molécule	 Verre
 Eau pour préparation injectable	 Non précisée
 Jour	 Polyvinyl chlorure
 Facteur influençant la stabilité	 Lumière
 Provoque	 Dégradation
 Absorption	 Compatibilités
 Précipitation immédiate	 Incompatible
 Chlorure de sodium 0,9%	 Turbidité immédiate
 Glucose 5%	 Compatible
 Aucun	 Incompatibilité non précisée
<b>RL</b> Ringer lactate	 Nutrition parentérale (mélange ternaire)
 Nutrition parentérale (mélange binaire)	 NaCl 0,9% + bactériostatique
 Solvant spécifique	 Turbidité en 1 heure
 Perte de turbidité	 Voie d'administration
 Perfusion intraveineuse	 Intramusculaire
 Sous cutanée	 Bibliographie
 Neuroleptique	 Solution buvable
 Stabilité des préparations	 Origine
 Excipient	 Flacon plastique
 Poudre	 Dictionnaire